France Legalizes CBD Cannabis Derived Products with THC below 0.3%

Jan.06.2023
France Legalizes CBD Cannabis Derived Products with THC below 0.3%
France legalizes sales of CBD-derived products with THC up to 0.3% but still bans sales of unprocessed cannabis flowers.

According to French media outlet RFI, on December 30th, 2021, the French government legalized the sale of cannabis-derived products containing CBD, with a THC content of no more than 0.3%, one year after lifting the ban on CBD. However, cannabis enthusiasts and those who favor Delta-8 (D8) may be disappointed to learn that the government still prohibits the sale of cannabis flowers, citing their supposed psychoactive effects.


However, a high court in France overturned the ban, ruling that CBD has not been proven harmful and that there are other legal uses for the plant besides smoking.


On December 29th, the French State Council (an institution that provides legislative proposals to the government and serves as the highest court) ruled that a comprehensive and absolute ban on the sale of raw forms of CBD was "disproportionate." They also found no conclusive evidence of harm from CBD. If any evidence exists, it is to the contrary.


The harmful effects of other molecules present in cannabis flowers and leaves, particularly CBD, have not yet been determined," the committee said. The committee added that there is evidence to suggest that CBD has "relaxing properties and anti-seizure effects, but no psychoactive effects, nor does it cause dependency.


In other words, the court ruled that marijuana should not automatically be classified as a psychoactive drug, as this is far from the truth. Additionally, it can be used not only for smoking, but also for making tea or infused oil. Other factors to consider are homemade tinctures or vaporizing the flowers.


Concerns about distinguishing between different types of cannabis.


Despite the recent court ruling allowing for cannabis cultivation, concerns have been raised about the government's plans to distinguish between cannabis and its highly potent derivative, tetrahydrocannabinol (THC), which is nearly indistinguishable to the naked eye. The State Council maintains that THC levels "can be controlled through rapid testing.


In November 2020, the European Court ruled that a ban on CBD that is legal in other European countries is illegal in France, based on the principle of free movement of goods.


The highest court of justice in France ruled in June of last year that any CBD produced legally in the European Union can be sold legally in France.


According to the French Professional Cannabis Association (SPC), as reported by RFI, there are now approximately 2,000 CBD shops operating in France. The industry's annual turnover is estimated to be around €500 million, or $534.1 million USD. More than half of these sales come solely from flowers.


Experts in the country have stated that the latest court ruling provides a green light for the economically sustainable cannabis industry that can withstand the test of time.


According to a report by Hemp Today, the French Senate committee has stated that legalizing cannabis in France could generate an annual revenue of 1.5 euros (160 billion USD) to 2.5 billion euros (260 billion USD) and create between 18,000-20,000 job opportunities.


The French extractive trade group, UIVEC, estimates that the grey market for CBD in France will be worth around 200 million euros ($214 million) by 2021, and is expected to reach about 300 million euros ($321 million) this year. UIVEC also estimates that by 2022, approximately 300-500 hectares of cannabis will be grown for hemp flower CBD production.


As legislation moves forward, these regulations are expected to be implemented in early 2023. The government is expected to announce that marijuana is in compliance with the European Union's common agriculture policy, develop an industry strategy, and create specific regulations.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

German Customs Seize 115,800 Vapes in €1.4 Million Tax Case
German Customs Seize 115,800 Vapes in €1.4 Million Tax Case
Germany's Magdeburg Main Customs Office seized 115,800 untaxed e-cigarettes containing a combined 4.366 million mL of e-liquid during four truck inspections between August 10 and September 4, 2026. The seizures prevented an estimated €1.397 million in tax losses and set a record for the customs office's jurisdiction. Criminal proceedings have been initiated against four truck drivers. The case follows a separate German investigation involving more than 7.6 million illicit vapes and an estimated €33.3 million in excise-tax losses.
Enforcement
Oct.13
Texas Extends Tobacco Tax Interpretation to a 6-Methylnicotine Product, Citing VELO Ruling
Texas Extends Tobacco Tax Interpretation to a 6-Methylnicotine Product, Citing VELO Ruling
The Texas Comptroller of Public Accounts ruled in September 2026 that a combustible product made with non-tobacco plant material and 6-methylnicotine (6-MN), a synthetic nicotine analog, qualifies as a taxable tobacco product. The applicant said the product contained neither tobacco leaf nor measurable conventional nicotine. The determination applies reasoning from a May Texas Supreme Court decision involving VELO nicotine pouches, finding that the plant material and 6-MN together perform the functions of tobacco in a conventional smoking product. The ruling carries applicable tax, licensing and reporting obligations but is limited to the facts submitted by the taxpayer. It does not establish a blanket tax classification for all 6-MN products or extend the same conclusion to e-cigarettes.
Regulations
Nov.06
Canada Recalls Nearly 25,000 GTMBAR Vapes Over Child-Resistant Packaging Violations; Brand Linked to Shenzhen GTM Bar, with LK Vape as Importer and Distributor
Canada Recalls Nearly 25,000 GTMBAR Vapes Over Child-Resistant Packaging Violations; Brand Linked to Shenzhen GTM Bar, with LK Vape as Importer and Distributor
Health Canada announced a recall of 24,950 China-made GTMBAR 45K disposable vaping devices on November 13, 2026, citing non-compliance with child-resistant packaging requirements. The devices were sold in Canada between December 2024 and October 2026 and feature a 20mL e-liquid system with a nicotine concentration of 20 mg/mL. No related incidents or injuries had been reported as of November 12. Quebec-based LK Vape is the Canadian importer and distributor, while Shenzhen GTM bar Electronic Technology Co., Ltd. holds the GTMBAR trademark registration in the United Kingdom.
Regulations
Nov.16
Ukraine Raises Excise Stamp Fees for Tobacco, Heated Tobacco and Vape Liquids by 30.5% as Parliament Backs E-Excise Delay to 2027
Ukraine Raises Excise Stamp Fees for Tobacco, Heated Tobacco and Vape Liquids by 30.5% as Parliament Backs E-Excise Delay to 2027
Ukraine's Cabinet of Ministers adopted Resolution No. 1259 on October 15, 2026, increasing excise stamp production fees for tobacco products and e-cigarette liquids by approximately 30.5%, from UAH 0.1643 to UAH 0.2144 per stamp. Fees for alcoholic beverages rose by about 30.2%. Separately, Ukraine's parliament passed Bill No. 15532 on October 13, proposing to postpone the full implementation of electronic excise stamps and traceability for alcohol, tobacco and e-cigarette liquids from November 1, 2026, to July 1, 2027. Parliament cited additional testing, configuration and integration requirements. The bill was sent to the president for signature on October 19.
Regulations
Oct.21
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
A U.S. Government Accountability Office audit found that 131,915 tobacco product applications submitted to the FDA since 2018 remained without a final review as of December 31, 2025, with pending applications waiting an average of 1,266 days. GAO also found FDA lacks the data needed to systematically determine whether scientific reviews meet applicable timelines. HHS agreed to upgrade the agency's tracking systems. At the same time, FDA has begun applying lessons from its nicotine pouch PMTA pilot to e-cigarette reviews, while changes to enforcement policy and electronic submissions are making the specific stage of a PMTA increasingly relevant to market access.
FDA
Oct.03
Product | Philip Morris Japan Teams Up With Renowned French Audio Brand DEVIALET for Limited-Edition IQOS Priced 60% Above Standard Model
Product | Philip Morris Japan Teams Up With Renowned French Audio Brand DEVIALET for Limited-Edition IQOS Priced 60% Above Standard Model
Philip Morris Japan (PMJ) launched the limited-edition IQOS ILUMA i PRIME Soundsorial Model in collaboration with French audio brand DEVIALET on October 1, 2026. Featuring sound-wave patterns, a silver-and-black finish and a gradient holder, the heated tobacco device is priced at JPY 15,980, including tax, and is available at four IQOS stores in Japan. According to Japanese media citing a PMJ representative, about 1,900 units were allocated to the Japanese retail market. A separate Soundsorial Collection, combining the device with DEVIALET Gemini II earbuds, includes 440 sets allocated to Japan for a membership prize draw.
product
Oct.23